{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:17:54Z","timestamp":1789186674460,"version":"build-2803163510"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.4103\/sjg.sjg_268_26","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:10:00Z","timestamp":1789143000000},"page":"379-393","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["TL1A inhibitors in inflammatory bowel disease: A systematic review of phase 2 clinical trials"],"prefix":"10.4103","volume":"32","author":[{"given":"Jeong-Gyu","family":"Choi","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Jeong","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea"},{"name":"Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Korea"},{"name":"Institute of New Frontier Research, Hallym University College of Medicine, Chuncheon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Seok","family":"Bang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea"},{"name":"Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Korea"},{"name":"Institute of New Frontier Research, Hallym University College of Medicine, Chuncheon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Jun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea"},{"name":"Department of Anesthesiology and Pain Medicine, Hallym University College of Medicine, Chuncheon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"R1-20260911","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R2-20260911","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn's disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"R3-20260911","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1074-7613(02)00283-2","article-title":"TL1A is a TNF-like ligand for DR3 and TR6\/DcR3 and functions as a T cell costimulator","volume":"16","author":"Migone","year":"2002","journal-title":"Immunity"},{"key":"R4-20260911","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/hmg\/ddi379","article-title":"Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease","volume":"14","author":"Yamazaki","year":"2005","journal-title":"Hum Mol Genet"},{"key":"R5-20260911","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/ajg.2008.36","article-title":"TNFSF15 polymorphisms are associated with susceptibility to inflammatory bowel disease in a new European cohort","volume":"104","author":"Thiebaut","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R6-20260911","doi-asserted-by":"crossref","first-page":"8441","DOI":"10.1073\/pnas.0510903103","article-title":"Role of TL1A and its receptor DR3 in two models of chronic murine ileitis","volume":"103","author":"Bamias","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"R7-20260911","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/mi.2013.114","article-title":"The TNF-family cytokine TL1A promotes allergic immunopathology through group 2 innate lymphoid cells","volume":"7","author":"Meylan","year":"2014","journal-title":"Mucosal Immunol"},{"key":"R8-20260911","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/25387","article-title":"Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer","volume":"396","author":"Pitti","year":"1998","journal-title":"Nature"},{"key":"R9-20260911","doi-asserted-by":"crossref","first-page":"e16090","DOI":"10.1371\/journal.pone.0016090","article-title":"Constitutive TL1A (TNFSF15) expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis","volume":"6","author":"Shih","year":"2011","journal-title":"PLoS One"},{"key":"R10-20260911","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa2314076","article-title":"Phase 2 Trial of Anti-TL1A monoclonal antibody tulisokibart for ulcerative colitis","volume":"391","author":"Sands","year":"2024","journal-title":"N Engl J Med"},{"key":"R11-20260911","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.cgh.2021.06.011","article-title":"Anti-TL1A antibody PF-06480605 safety and efficacy for ulcerative colitis: A phase 2a single-arm study","volume":"19","author":"Danese","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R12-20260911","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/ibd\/izab193","article-title":"Antitumor necrosis factor-like ligand 1A therapy targets tissue inflammation and fibrosis pathways and reduces gut pathobionts in ulcerative colitis","volume":"28","author":"Hassan-Zahraee","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"R13-20260911","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S2468-1253(25)00129-3","article-title":"Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): A multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial","volume":"10","author":"Danese","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R14-20260911","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(26)00120-2","article-title":"Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): A phase 2b, randomised, placebo-controlled trial","author":"Reinisch","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R16-20260911","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R17-20260911","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R18-20260911","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"R19-20260911","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R20-20260911","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R21-20260911","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R22-20260911","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"R23-20260911","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"R24-20260911","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"R25-20260911","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S2468-1253(25)00071-8","article-title":"Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: A phase 2a induction trial","volume":"10","author":"Feagan","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R26-20260911","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(26)00119-6","article-title":"Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): A phase 2b, randomised, placebo-controlled trial","author":"Jairath","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"(Suppl)","key":"R28-20260911","first-page":"S38","article-title":"Duvakitug, an anti-TL1a mAb, demonstrates efficacy and favorable safety as an induction treatment in adults with moderately to severely active Crohn's Disease: Results from the RELIEVE UCCD Phase 2b basket trial","volume":"120","author":"Jairath","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"R29-20260911","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/S2468-1253(25)00204-3","article-title":"Correction to Lancet Gastroenterol Hepatol 2025;10:715-25","volume":"10","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R30-20260911","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"R34-20260911","doi-asserted-by":"crossref","first-page":"jjag039","DOI":"10.1093\/ecco-jcc\/jjag039","article-title":"TL1A as a therapeutic renaissance in inflammatory bowel disease: A systematic review from molecular mechanisms to clinical translation","volume":"20","author":"Liang","year":"2026","journal-title":"J Crohns Colitis"},{"key":"R35-20260911","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/apt.70648","article-title":"Review article: TL1A inhibitors in IBD \u2013 mechanistic rationale and clinical evidence","volume":"63","author":"Goyal","year":"2026","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_268_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:10:04Z","timestamp":1789143004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_268_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/sjg.sjg_268_26","relation":{},"ISSN":["1319-3767","1998-4049"],"issn-type":[{"value":"1319-3767","type":"print"},{"value":"1998-4049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-06-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}